Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.
Sara Tolaney, MD, MPH, associate director of the Susan F. Smith Center for Women’s Cancers; director of Clinical Trials, Breast Oncology; and senior physician at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, discusses sacituzumab govitecan-hziy (Trodelvy) as an effective and safe treatment for patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer.
Data from the final overall survival (OS) analysis of TROPiCS-02 (NCT03901339) revealed there to be a confirmed clinically meaningful OS benefit with sacituzumab govitecan vs with single-agent chemotherapy in this patient population, further supporting the FDA approval.
Based on findings from the study, the FDA granted approval to sacituzumab govitecan.
Transcription:
0:10 | TROPiCS-02 is a phase 3 study that compared sacituzumab govitecan to treatment of physicians choice chemotherapy in patients with metastatic hormone receptor-positive disease. Eligible patients were required to have had prior CDK4/6 inhibition, prior endocrine therapy, prior taxane, and also 2 to 4 prior lines of chemotherapy in the metastatic setting, and also needed measurable disease. They were then randomized in a 1:1 fashion to get sacituzumab govitecan given at the standard schedule of 10 mg/kg [intravenously] on days 1 and 8 of a 21 day cycle, or to get treatment of physicians choice chemotherapy. The primary end point was progression-free survival. Key secondary end points did include overall survival and objective response rate.
1:34 | At the time of this analysis, which again is a final exploratory overall survival analysis, there was a median follow-up time of 13 months. At this time, there were about 438 overall survival events. We did see that sacituzumab govitecan did improve overall survival. It was 14.5 months with sacituzumab govitecan compared with 11.2 months with treatment of physicians choice chemotherapy, with a hazard ratio of 0.79, suggesting statistically significant improvements in overall survival, but I think also clinically meaningful differences in overall survival.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More